ATRC Stock Analysis: AtriCure | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.610m USD | 12M Return: 6.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.7M
Qual. Beats: 6
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AtriCure, Inc. is a medical device company that develops, manufactures, and sells surgical ablation systems, left atrial appendage exclusion devices, and peripheral nerve ablation products for pain management. Its products serve hospitals and medical centers across the United States, Asia-Pacific, and other international markets. The company operates within the cardiac surgery and electrophysiology segments of the broader medical device industry, focusing on treatment of atrial fibrillation and related cardiac arrhythmias.
The companys product portfolio centers on two main ablation technologies: radiofrequency (RF) devices, including the Isolator Synergy Ablation System and EPi-Sense Systems, and cryoablation platforms such as the cryoICE Cryoablation System and cryoSPHERE probe. It also offers the AtriClip System for left atrial appendage closure, the LARIAT System for soft-tissue closure, and various reusable surgical instruments. This dual-technology approach (RF and cryothermal) is a common strategy in the surgical ablation market, allowing providers to select the modality best suited to specific procedures and patient anatomies.
AtriCure distributes its products through a combination of independent distributors and direct sales personnel, a hybrid model typical of U.S.-based medical device firms seeking international reach while maintaining direct customer relationships in core markets. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- Convergent procedure adoption accelerates US atrial fibrillation revenue
- CryoSPHERE pain management expands into new surgical indications
- Competition from catheter ablation pressures hybrid surgical market share
| Net Income: -4.59m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 8.44 > 1.0 |
| NWC/Revenue: 43.56% < 20% (prev 39.63%; Δ 3.92% < -1%) |
| CFO/TA 0.10 > 3% & CFO 64.4m > Net Income -4.59m |
| Net Debt (-60.5m) to EBITDA (24.7m): -2.45 < 3 |
| Current Ratio: 4.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.0m) vs 12m ago 3.49% < -2% |
| Gross Margin: 75.47% > 18% (prev 74.60%; Δ 0.87% > 0.5%) |
| Asset Turnover: 89.37% > 50% (prev 81.14%; Δ 8.23% > 0%) |
| Interest Coverage Ratio: 0.55 > 6 (EBIT TTM 3.98m / Interest Expense TTM 7.24m) |
| A: 0.37 (Total Current Assets 313.7m - Total Current Liabilities 73.2m) / Total Assets 644.0m |
| B: -0.64 (Retained Earnings -413.1m / Total Assets 644.0m) |
| C: 0.01 (EBIT TTM 3.98m / Avg Total Assets 617.8m) |
| D: 3.23 (Book Value of Equity 491.7m / Total Liabilities 152.3m) |
| Altman-Z'' = 3.79 = AA |
| DSRI: 0.98 (Receivables 71.3m/63.3m, Revenue 552.2m/480.1m) |
| GMI: 0.99 (GM 74.60% / 75.47%) |
| AQI: 0.89 (AQ_t 0.44 / AQ_t-1 0.49) |
| SGI: 1.15 (Revenue 552.2m / 480.1m) |
| TATA: -0.11 (NI -4.59m - CFO 64.4m) / TA 644.0m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 34.28 with a total of 517,774 shares traded. Over the past week, the price has changed by +7.83%, over one month by +24.61%, over three months by +21.43% and over the past year by +6.92%.
Current recommended Stop Loss: 32.30 (which is 5.8% or 1.3 ATR below the current price).
AtriCure has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy ATRC.
- StrongBuy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47 | 37.1% |
P/E Forward = 400.0
P/S = 2.9156
P/B = 3.2752
P/EG = 10.0
Revenue TTM = 552.2m USD
EBIT TTM = 3.98m USD
EBITDA TTM = 24.7m USD
Long Term Debt = 61.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.13m USD (from shortTermDebt, last quarter)
Debt = 85.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 10.8m
Net Debt = -60.5m USD (calculated: Debt 85.7m - CCE 146.2m)
Enterprise Value = 1.55b USD (1.61b + Debt 85.7m - CCE 146.2m)
Interest Coverage Ratio = 0.55 (Ebit TTM 3.98m / Interest Expense TTM 7.24m)
EV/FCF = 28.88x (Enterprise Value 1.55b / FCF TTM 53.6m)
FCF Yield = 3.46% (FCF TTM 53.6m / Enterprise Value 1.55b)
FCF Margin = 9.72% (FCF TTM 53.6m / Revenue TTM 552.2m)
Net Margin = -0.83% (Net Income TTM -4.59m / Revenue TTM 552.2m)
Gross Margin = 75.47% ((Revenue TTM 552.2m - Cost of Revenue TTM 135.5m) / Revenue TTM)
Gross Margin QoQ = 77.39% (prev 74.43%)
Tobins Q-Ratio = 2.41 (Enterprise Value 1.55b / Total Assets 644.0m)
Interest Expense / Debt = 8.45% (Interest Expense 7.24m / Debt 85.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 3.14m (EBIT 3.98m * (1 - 21.00%))
Current Ratio = 4.29 (Total Current Assets 313.7m / Total Current Liabilities 73.2m)
Debt / Equity = 0.17 (Debt 85.7m / totalStockholderEquity, last quarter 491.7m)
Debt / EBITDA = -2.45 (Net Debt -60.5m / EBITDA 24.7m)
Debt / FCF = -1.13 (Net Debt -60.5m / FCF TTM 53.6m)
Total Stockholder Equity = 481.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.74% (Net Income -4.59m / Total Assets 644.0m)
RoE = -0.95% (Net Income TTM -4.59m / Total Stockholder Equity 481.2m)
RoCE = 0.73% (EBIT 3.98m / Capital Employed (Equity 481.2m + L.T.Debt 61.0m))
RoIC = 0.58% (NOPAT 3.14m / Invested Capital 546.3m)
WACC = 8.26% (E(1.61b)/V(1.70b) * Re(8.34%) + D(85.7m)/V(1.70b) * Rd(8.45%) * (1-Tc(0.21)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 2.45%
[DCF] Terminal Value 75.44% ; FCFF base≈53.6m ; Y1≈53.9m ; Y5≈57.1m
[DCF] Fair Price = 18.72 (EV 887.5m - Net Debt -60.5m = Equity 947.9m / Shares 50.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.12 | # QB: 6
Revenue Correlation: 99.91 | Revenue CAGR: 16.17% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.02 | Chg30d=N/A | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.02 | Chg30d=-68.06% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=0.12 | Chg30d=-12.93% | Revisions=+0% | GrowthEPS=+210.8% | GrowthRev=+13.2%
EPS next Year (2027-12-31): EPS=0.35 | Chg30d=-5.65% | Revisions=-25% | GrowthEPS=+186.2% | GrowthRev=+12.2%
[Analyst] Revisions Ratio: -12% (up=2, down=3)